145 related articles for article (PubMed ID: 15728417)
1. Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis.
Manneschi LI; Del Rosso A; Milia AF; Tani A; Nosi D; Pignone A; Generini S; Giacomelli R; Cerinic MM
Rheumatology (Oxford); 2005 May; 44(5):607-13. PubMed ID: 15728417
[TBL] [Abstract][Full Text] [Related]
2. [Peripheral nervous system in limited systemic sclerosis].
Del Rosso A; Ibba Manneschi L; Tani A; Nosi D; Franca Milia A; Generini S; Guiducci S; Melchiorre D; Pignone A; Matucci Cerinic M
Reumatismo; 2004; 56(4):247-52. PubMed ID: 15643479
[TBL] [Abstract][Full Text] [Related]
3. Pupillocynetic activity of substance P in systemic sclerosis.
Del Rosso A; Bertinotti L; Pietrini U; Messori A; Fanciullacci M; Casale R; Giacomelli R; Generini S; Sicuteri R; Pignone A; Cozzi F; Matucci-Cerinic M
J Rheumatol; 2003 Jun; 30(6):1231-7. PubMed ID: 12784395
[TBL] [Abstract][Full Text] [Related]
4. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis.
Crilly A; Hamilton J; Clark CJ; Jardine A; Madhok R
Rheumatology (Oxford); 2003 Nov; 42(11):1295-8. PubMed ID: 12867583
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
8. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.
Furst DE; Clements PJ; Steen VD; Medsger TA; Masi AT; D'Angelo WA; Lachenbruch PA; Grau RG; Seibold JR
J Rheumatol; 1998 Jan; 25(1):84-8. PubMed ID: 9458208
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
[TBL] [Abstract][Full Text] [Related]
10. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.
Gruschwitz MS; Albrecht M; Vieth G; Haustein UF
J Rheumatol; 1997 Oct; 24(10):1936-43. PubMed ID: 9330935
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers.
Del Rosso A; Boldrini M; D'Agostino D; Placidi GP; Scarpato A; Pignone A; Generini S; Konttinen Y; Zoppi M; Vlak T; Placidi G; Matucci-Cerinic M
Arthritis Rheum; 2004 Jun; 51(3):475-81. PubMed ID: 15188336
[TBL] [Abstract][Full Text] [Related]
14. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis.
Hasegawa M; Sato S; Takehara K
Arch Dermatol Res; 2004 Jul; 296(2):89-93. PubMed ID: 15133694
[TBL] [Abstract][Full Text] [Related]
15. Vascular damage and lack of angiogenesis in systemic sclerosis skin.
Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I
Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210
[TBL] [Abstract][Full Text] [Related]
16. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis.
Cutolo M; Sulli A; Pizzorni C; Accardo S
J Rheumatol; 2000 Jan; 27(1):155-60. PubMed ID: 10648032
[TBL] [Abstract][Full Text] [Related]
17. Increased pigmentation in scleroderma.
Pope JE; Shum DT; Gottschalk R; Stevens A; McManus R
J Rheumatol; 1996 Nov; 23(11):1912-6. PubMed ID: 8923365
[TBL] [Abstract][Full Text] [Related]
18. Relationship between cutaneous and pulmonary involvement in systemic sclerosis.
Morelli S; Barbieri C; Sgreccia A; Ferrante L; Pittoni V; Conti F; Gualdi G; Polettini E; Carlesimo OA; Calvieri S
J Rheumatol; 1997 Jan; 24(1):81-5. PubMed ID: 9002015
[TBL] [Abstract][Full Text] [Related]
19. Severe organ involvement in systemic sclerosis with diffuse scleroderma.
Steen VD; Medsger TA
Arthritis Rheum; 2000 Nov; 43(11):2437-44. PubMed ID: 11083266
[TBL] [Abstract][Full Text] [Related]
20. Brachial plexopathy associated with diffuse edematous scleroderma.
Mouthon L; Halimi C; Dussaule Md JC; Cayre-Castel Md M; Guillevin L
Ann Med Interne (Paris); 2000 Jun; 151(4):303-5. PubMed ID: 10922959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
